Placebos in clinic and research: Experimental findings and theoretical concepts;Plazebos in klinik und forschung: Experimentelle befunde und theoretische konzepte

PPmP Psychotherapie Psychosomatik Medizinische Psychologie

Volumn 55, Issue 9-10, 2005, Pages 433-441

  Klosterhalfen, Sibylle ^a   Enck, Paul ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Clinical trials; Functional bowel disorders; Nocebo; Placebo

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PEPPERMINT OIL; PLACEBO; PROKINETIC AGENT; SPASMOLYTIC AGENT;

ARTICLE; CLINICAL RESEARCH; CONDITIONING; DEPRESSION; DYSPEPSIA; GENETIC PREDISPOSITION; HUMAN; MEDLINE; NEUROIMAGING; PARKINSON DISEASE; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; PSYCHOLOGY; PSYCHOTHERAPY; SUGGESTION; SYSTEMATIC REVIEW;

CLINICAL TRIALS; CONDITIONING, CLASSICAL; HUMANS; PLACEBO EFFECT; RESEARCH; RESEARCH DESIGN; SIGNAL DETECTION (PSYCHOLOGY);

EID: 25144453744     PISSN: 09372032     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-866915     Document Type: Article

References (75)

1. Klosterhalfen S, Enck P. Psychobiology of the placebo response. J Auton Neurosci, 2005 (im Druck)
2. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Mot 2005; 17: 325-331
3. Patel SM, Ock SM, Stason W et al. The placebo effect in irritable bowel syndrome (IBS) trials: A meta-analysis. Neurogastroenterol Mot 2005; 17: 332-340
4. Mearin F, Balboa A, Zarate N et al. Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999; 94: 116-125
5. Allescher HD, Bockenhoff A, Knapp G et al. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-941
6. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle elaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-361
7. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86
8. Jackson JL, O'Malley PG, Tomkins G et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72
9. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med 2003; 163: 265-274
10. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-241
11. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107, Suppl: 91S-97S
12. Ilnyckyj A, Shanahan F, Anton PA et al. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-1858
13. Su C, Lichtenstein GR, Krok K et al. A meta-analysis of the placebo response rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-1269
14. Moerman DE, Jonas WB. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002; 136: 471-476
15. Craen AJ de, Moerman DE, Heisterkamp SH et al. Placebo effect in the treatment of duodenal ulcer. Br J Clin Pharmacol 1999; 48: 853-860
16. Weihrauch TR, Gauler TC. Placebo - efficacy and adverse effects in controlled clinical trials. Arzneimittelforschung 1999; 49: 385-393
17. Moerman DE. Cultural variations in the placebo effect: ulcers, anxiety, and blood pressure. Med Anthropol Q 2000; 14: 51-72
18. Moncrieff J, Wessely S, Hardy R. Antidepressants using active placebos. Cochrane Database Syst Rev, 2001 CD003012
19. Enserink M. Can the placebo be the cure? Science 1999; 284: 238-240
20. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment 1998; 12: http://apa.org/journals/prevention/volumel (posted: June 26, 1998)
21. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression - variable, substantial, and growing. JAMA 2002; 287: 1840-1847
22. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602
23. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004; 256: 91-100
24. rd JL, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 2002; 99: 443-452
25. Welge JA, Keck Jr PE. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl) 2003; 166: 1-10
26. Robertson C, Idris NR, Boyle P. Beyond classical meta-analysis: can inadequately reported studies be included? Drug Discov Today 2004; 9: 924-931
27. Moayyedi P. Meta-analysis: Can we mix apples with oranges? Am J Gastroenterol 2004; 99: 2297-2301
28. Chey WD, Chey WY, Heath AT et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2185-2203
29. Gordon S, Ameen V, Bagby B et al. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003; 48: 1317-1323
30. Rollman GB. Signal detection theory measurement of pain: a review and critique. Pain 1977; 3: 187-211
31. Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. Eval Health Prof 2002; 25: 410-420
32. Sullivan MD, Katon WJ, Russo JE et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract 2003; 16: 22-31
33. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med 2002; 136 (11): 817-825
34. Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 2003; 105: 17-25
35. Verne GN, Robinson ME, Vase L, Price DD. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 2003; 105: 223-230
36. Pascalis V De, Chiaradia C, Carotenuto E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 2002; 96: 393-402
37. Reynaert C, Janne P, Vause M et al. Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome. Psychopharmacology (Berl) 1995; 119: 449-454
38. Roelofs J, Riet G ter, Peters ML et al. Expectations of analgesia do not affect spinal nociceptive R-III reflex activity: an experimental study into the mechanism of placebo-induced analgesia. Pain 2000; 89: 75-80
39. Pavlov IP. Gesammelte Werke: Über die Physiologie und Pathophysiologie der höheren Nerventätigkeit (Ed. L. Pickenhain). Würzburg: ERGON Publ, 1998
40. Craen AJ de, Roos PJ, Leonard de Vries A, Kleijnen J. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996; 313: 1624-1626
41. Lindbaek M, Sandvik E, Liodden K et al. Predictors for the white coat effect in general practice patients with suspected and treated hypertension. Br J Gen Pract 2003; 53 (495): 790-793
42. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002; 295: 1737-1740
43. Wager TD, Rittling JK, Smith EE et al. Placebo-induced changes in fMRI in the anticipation and experience of pain. Science 2004; 303: 1162-1167
44. Benedetti F, Arduino C, Amanzio M. Somatotopic activation of opioid systems by target-directed expectations of analgesia. J Neurosci 1999; 19: 3639-3648
45. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci 1999; 19: 484-494
46. White PJ. Methodological concerns when designing trials for the efficacy of acupuncture for the treatment of pain. Adv Exp Med Biol 2004; 546: 217-227
47. Streitberger K, Kleinhenz J. Introducing a placebo needle into acupuncture research. Lancet 1998; 352: 364-365
48. Streitberger K, Friedrich-Rust M, Bardenheuer H et al. Effect of acupuncture compared with placebo-acupuncture at P6 as additional antiemetic prophylaxis in high-dose chemotherapy and autologous peripheral blood stem cell transplantation: a randomized controlled single-blind trial. Clin Cancer Res 2003; 9: 2538-2544
49. Benedetti F, Pollo A, Lopiano L et al. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003; 23: 4315-4323
50. Fuente-Fernandez R de la, Ruth TJ, Sossi V et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166
51. Fuente-Fernandez R de la, Phillips AG, Zamburlini M et al. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002; 15: 359-363
52. Benedetti F, Colloca L, Torre E et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neurosci 2004; 7: 587-588
53. Leuchter AF, Cook IA, Witte EA et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-129
54. Mayberg HS, Silva JA, Brannan SK et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737
55. Lieberman MD, Jarcho JM, Berman S et al. The neural correlates of placebo effects: a disruption account. NeuroImage 2004; 22: 447-455
56. Wood JN, Grafman J. Human prefrontal cortex: processing and representational perspectives. Nat Rev Neurosci 2003; 4: 139-147
57. 3 receptor antagonist Alosetron. Gastroenterology 2002; 123: 969-977
58. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 1997; 26: 607-611
59. Benson H. The nocebo effect: history and physiology. Prev med 1997; 26: 612-615
60. Liccardia G, Senna G, Russo M et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reaction. J Investig Allergol Clin Immunol 2004; 14: 104-107
61. Kasdan ML, Lewis K, Bruner A, Hohnson AL. The nocebo effect: Do no harm. J South Orthop Assoc 1999; 8: 108-113
62. Bellamy R. Compensation neurosis: financial reward for illness as nocebo. Clin Orthop Relat Res 1997; 336: 94-106
63. Fishbain DA, Goldberg M. The misdiagnosis of conversion disorder in a psychiatric emergency service. Gen Hosp Psychiatry 1991; 13: 177-181
64. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122: 1701-1714
65. Flamen MA, Simonsen T, Olsen H. Drug-related information generates placebo and nocebo responses that modify the drug response. Psychosom Med 1999; 61: 250-255
66. Johanson O, Brox J, Flamen MA. Placebo and nocebo responses, cortisol, and circulating beta-endophin. Psychosom Med 2003; 65: 786-790
67. Staats PS, Staats A, Hekmat H. The additive impact of anxiety and a placebo on pain. Pain Med 2001; 2: 267-279
68. Hunter AM, Leuchter AF, Morgan ML et al. Neurophysiological correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 2005; 30: 792-799
69. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-627
70. Enck P, Klosterhalfen S, Kruis W. Determinanten der Plazebowirkung beim Reizdarm-Syndrom. Deutsche Medizinische Wochenschrift, 2005; 130: im Druck
71. Evans D. Suppression of the acute-phase response as a biological mechanism for the placebo effect. Med Hypoth 2005; 64: 1-7
72. Bendesky A, Sonabend AM. On Schleppfuss' path: the placebo response in human evolution. Med Hypoth 2005; 64: 414-416
73. Shapiro AK, Shapiro E. Then placebo: is it much ado about nothing? In: Harrington A (ed): The placebo effect. An interdisciplinary exploration. Cambridge/London: Harvard University Press, 1999: 12-36
74. Klosterhalfen W, Klosterhalfen S. Pavlovian conditioning of immunosuppression modifies adjuvant arthritis in rats. Behav Neurosci 1983; 97: 663-666
75. Goebel MU, Trebst AE, Steiner J et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J 2002; 16: 1869-1873